Vicky Lee Ng1, Barbara H Haber2, John C Magee3, Alexander Miethke4, Karen F Murray5, Sonia Michail6, Saul J Karpen7, Nanda Kerkar8, Jean P Molleston9, Rene Romero10, Philip Rosenthal11, Kathleen B Schwarz12, Benjamin L Shneider13, Yumirle P Turmelle14, Estella M Alonso15, Averell H Sherker16, Ronald J Sokol17. 1. Division of Pediatric Gastroenterology, Hepatology, and Nutrition, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada. Electronic address: vicky.ng@sickkids.ca. 2. Division of Gastroenterology and Nutrition, Children's Hospital of Philadelphia, Philadelphia, PA. 3. Department of Surgery, University of Michigan Medical School, Ann Arbor, MI. 4. Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Cincinnati Children's Hospital Medical Center, Cincinnati, OH. 5. Hepatobiliary Program, Seattle Children's Hospital and University of Washington, Seattle, WA. 6. Department of Gastroenterology and Nutrition, Children's Hospital Los Angeles, Keck School of Medicine University of Southern California, Los Angeles, CA. 7. Texas Children's Hospital, Houston, TX; Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Children's Healthcare of Atlanta, Emory University, Atlanta, GA. 8. Department of Gastroenterology and Nutrition, Children's Hospital Los Angeles, Keck School of Medicine University of Southern California, Los Angeles, CA; Division of Pediatric Hepatology, Mount Sinai School of Medicine, New York, NY. 9. Pediatric Gastroenterology, Hepatology, and Nutrition, Riley Hospital for Children, Indiana University, Indianapolis, IN. 10. Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Children's Healthcare of Atlanta, Emory University, Atlanta, GA. 11. Pediatrics Gastroenterology, Hepatology, and Nutrition, University of California San Francisco Benioff Children's Hospital, University of California, San Francisco, CA. 12. Division of Pediatric Gastroenterology and Nutrition, Johns Hopkins Medical Institutions, Baltimore, MD. 13. Department of Pediatric Gastroenterology, Hepatology, and Nutrition, Children's Hospital Pittsburgh of University of Pittsburgh Medical Center, Pittsburgh, PA. 14. Division of Gastroenterology and Nutrition, Washington University, St. Louis, MO. 15. Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Ann and Robert H. Lurie Children's Hospital and Northwestern University, Chicago, IL. 16. Liver Diseases Research Branch, NIDDK, NIH, Bethesda, MD. 17. Department of Gastroenterology, Hepatology, and Nutrition, University of Colorado School of Medicine, Children's Hospital Colorado, Aurora, CO.
Abstract
OBJECTIVES: To examine the medical status of children with biliary atresia (BA) with their native livers after hepato- portoenterostomy (HPE) surgery. STUDY DESIGN: The Childhood Liver Disease Research and Education Network database was utilized to examine subjects with BA living with their native livers 5 or more years after HPE and to describe the prevalence of subjects with BA with an "ideal" outcome, defined as no clinical evidence of chronic liver disease, normal liver biochemical indices (aspartate aminotransferase, alanine aminotransferase, γ-glutamyl transpeptidase, platelet count, total bilirubin, international normalized ratio, and albumin), and normal health-related quality of life 5 or more years after HPE. RESULTS: Children with BA (n = 219; 43% male) with median age 9.7 years were studied. Median age at HPE was 56 (range 7-125) days. Median age- and sex-adjusted height and weight z-scores at 5-year follow-up were 0.487 (IQR -0.27 to 1.02) and 0.00 (IQR -0.74 to 0.70), respectively. During the 12 preceding months, cholangitis and bone fractures occurred in 17% and 5.5%, respectively. Health-related quality of life was reported normal by 53% of patients. However, only 1.8% met the study definition of "ideal" outcome. Individual tests of liver synthetic function (total bilirubin, albumin, and international normalized ratio) were normal in 75%, 85%, and 73% of the study cohort. CONCLUSION: Cholangitis and fractures in long-term survivors underscore the importance of ongoing medical surveillance. Over 98% of this North American cohort of subjects with BA living with native livers 5 or more years after HPE have clinical or biochemical evidence of chronic liver disease.
OBJECTIVES: To examine the medical status of children with biliary atresia (BA) with their native livers after hepato- portoenterostomy (HPE) surgery. STUDY DESIGN: The Childhood Liver Disease Research and Education Network database was utilized to examine subjects with BA living with their native livers 5 or more years after HPE and to describe the prevalence of subjects with BA with an "ideal" outcome, defined as no clinical evidence of chronic liver disease, normal liver biochemical indices (aspartate aminotransferase, alanine aminotransferase, γ-glutamyl transpeptidase, platelet count, total bilirubin, international normalized ratio, and albumin), and normal health-related quality of life 5 or more years after HPE. RESULTS:Children with BA (n = 219; 43% male) with median age 9.7 years were studied. Median age at HPE was 56 (range 7-125) days. Median age- and sex-adjusted height and weight z-scores at 5-year follow-up were 0.487 (IQR -0.27 to 1.02) and 0.00 (IQR -0.74 to 0.70), respectively. During the 12 preceding months, cholangitis and bone fractures occurred in 17% and 5.5%, respectively. Health-related quality of life was reported normal by 53% of patients. However, only 1.8% met the study definition of "ideal" outcome. Individual tests of liver synthetic function (total bilirubin, albumin, and international normalized ratio) were normal in 75%, 85%, and 73% of the study cohort. CONCLUSION:Cholangitis and fractures in long-term survivors underscore the importance of ongoing medical surveillance. Over 98% of this North American cohort of subjects with BA living with native livers 5 or more years after HPE have clinical or biochemical evidence of chronic liver disease.
Authors: Shikha S Sundaram; Estella M Alonso; Barbara Haber; John C Magee; Emily Fredericks; Binita Kamath; Nanda Kerkar; Philip Rosenthal; Ross Shepherd; Christine Limbers; James W Varni; Patricia Robuck; Ronald J Sokol Journal: J Pediatr Date: 2013-06-06 Impact factor: 4.406
Authors: Benjamin L Shneider; Bob Abel; Barbara Haber; Saul J Karpen; John C Magee; Rene Romero; Kathleen Schwarz; Lee M Bass; Nanda Kerkar; Alexander G Miethke; Philip Rosenthal; Yumirle Turmelle; Patricia R Robuck; Ronald J Sokol Journal: J Pediatr Gastroenterol Nutr Date: 2012-11 Impact factor: 2.839
Authors: Kathleen B Schwarz; Barbara H Haber; Philip Rosenthal; Cara L Mack; Jeffrey Moore; Kevin Bove; Jorge A Bezerra; Saul J Karpen; Nanda Kerkar; Benjamin L Shneider; Yumirle P Turmelle; Peter F Whitington; Jean P Molleston; Karen F Murray; Vicky L Ng; René Romero; Kasper S Wang; Ronald J Sokol; John C Magee Journal: Hepatology Date: 2013-09-19 Impact factor: 17.425
Authors: Patricia A DeRusso; Wen Ye; Ross Shepherd; Barbara A Haber; Benjamin L Shneider; Peter F Whitington; Kathleen B Schwarz; Jorge A Bezerra; Philip Rosenthal; Saul Karpen; Robert H Squires; John C Magee; Patricia R Robuck; Ronald J Sokol Journal: Hepatology Date: 2007-11 Impact factor: 17.425
Authors: Lee M Bass; Benjamin L Shneider; Lisa Henn; Nathan P Goodrich; John C Magee Journal: J Pediatr Gastroenterol Nutr Date: 2019-06 Impact factor: 2.839
Authors: Jorge A Bezerra; Rebecca G Wells; Cara L Mack; Saul J Karpen; Jay H Hoofnagle; Edward Doo; Ronald J Sokol Journal: Hepatology Date: 2018-09 Impact factor: 17.425
Authors: Maria Hukkinen; Jouko Lohi; Päivi Heikkilä; Reetta Kivisaari; Timo Jahnukainen; Hannu Jalanko; Mikko P Pakarinen Journal: Hepatol Commun Date: 2019-01-09